|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1992-3-19
|
|
pubmed:abstractText |
Mesna is used to abolish urotoxicity of cyclophosphamide and related compounds in immunosuppressive and antineoplastic treatment schedules. Adverse reactions to this drug have been reported only rarely.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0003-987X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
128
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
80-2
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:1531405-Adult,
pubmed-meshheading:1531405-Biopsy,
pubmed-meshheading:1531405-Cyclophosphamide,
pubmed-meshheading:1531405-Dermatomyositis,
pubmed-meshheading:1531405-Drug Eruptions,
pubmed-meshheading:1531405-Drug Therapy, Combination,
pubmed-meshheading:1531405-Female,
pubmed-meshheading:1531405-Humans,
pubmed-meshheading:1531405-Lupus Erythematosus, Systemic,
pubmed-meshheading:1531405-Male,
pubmed-meshheading:1531405-Mesna,
pubmed-meshheading:1531405-Methylprednisolone,
pubmed-meshheading:1531405-Metoclopramide,
pubmed-meshheading:1531405-Middle Aged,
pubmed-meshheading:1531405-Patch Tests,
pubmed-meshheading:1531405-Skin
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Drug eruptions from mesna. After cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis.
|
|
pubmed:affiliation |
Department of Dermatology I, University of Vienna Medical School, Austria.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
